Menu
PhRMA recently urged CMS to establish a neutral clearinghouse and require accurate use of 340B claim modifiers to address nonduplication in its final guidance for Medicare drug price negotiations under the IRA.

Drug Industry Takes Issue with IRA’s Drug Negotiation Guidance

Shannon Young, Associate Editor/Senior Writer 340B Report Views
Editor’s Note: In Tuesday’s issue, we looked at comments from 340B provider stakeholders, today we look more closely at the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

New Hampshire Enacts Law to Bar PBMs, Payers from ‘Discriminating Against’ 340B Providers

Pharma-Linked Conservative Nonprofit Launches Ad Campaign to ‘Stop the Feeding Frenzy’ in 340B

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Quick verification required before signup

Site Footer Live